University of Texas MD Anderson Cancer Center.
Clin J Oncol Nurs. 2020 Aug 1;24(4):392-398. doi: 10.1188/20.CJON.392-398.
Acalabrutinib is a selective Bruton tyrosine kinase inhibitor approved for patients with relapsed or refractory mantle cell lymphoma, an aggressive B-cell malignancy. Treatment-related adverse events (AEs) can have a negative effect on treatment adherence.
This article aims to provide nurses with firsthand guidance so that they can better support patients with mantle cell lymphoma initiating acalabrutinib.
Safety data from the acalabrutinib ACE-LY-004 phase 2 trial in 124 patients with relapsed or refractory mantle cell lymphoma were reviewed, and strategies implemented at the University of Texas MD Anderson Cancer Center to manage trial AEs are described.
The most common AEs of any grade were headache and diarrhea, but no patients discontinued treatment because of them. When doses were missed or modified, patients were reeducated about the importance of adherence and how to manage AEs. Grade 1-2 AEs were managed with over-the-counter medication, if needed. These strategies allowed for the tracking of occurrences of nonadherence, providing the opportunity to advise and educate patients and to manage AEs more effectively.
阿卡替尼是一种选择性布鲁顿酪氨酸激酶抑制剂，已被批准用于治疗复发或难治性套细胞淋巴瘤，这是一种侵袭性 B 细胞恶性肿瘤。与治疗相关的不良事件（AE）可能会对治疗依从性产生负面影响。
本文旨在为护士提供第一手指导，以便他们能够更好地支持开始使用阿卡替尼治疗的套细胞淋巴瘤患者。
回顾了在 124 例复发或难治性套细胞淋巴瘤患者中进行的阿卡替尼 ACE-LY-004 期 2 试验的安全性数据，并描述了德克萨斯大学 MD 安德森癌症中心实施的管理试验 AE 的策略。
任何级别的最常见 AE 是头痛和腹泻，但没有患者因这些 AE 而停止治疗。当错过或调整剂量时，对患者进行了再教育，强调了坚持治疗的重要性以及如何管理 AE。如果需要，1-2 级 AE 采用非处方药物进行治疗。这些策略能够跟踪不依从的发生情况，为提供建议和教育患者以及更有效地管理 AE 提供了机会。
